Gene · 4593
Papers3,141
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 3,141
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| FcRn Blockade as a Targeted Therapeutic Strategy in Antibody-Mediated Autoimmune Diseases: A Focus on Warm Autoimmune Hemolytic Anemia. | Antibodies (Basel) | 2025 | 40843677 | PubTator, text mining | PubMed |
| Factors Influencing Quality of Life in Myasthenia Gravis Patients: Results From a Cross-Sectional Study in South of Iran. | Brain Behav | 2025 | 40842108 | PubTator, text mining | PubMed |
| B Cell Tolerance and BCR Signaling Dysregulation in NF155-Mediated Autoimmune Nodopathies. | bioRxiv | 2025 | 40832342 | PubTator, text mining | PubMed |
| The efficacy and safety of efgartigimod for refractory myasthenia gravis: a systematic review and meta-analysis. | Eur J Med Res | 2025 | 40830529 | PubTator, text mining | PubMed |
| Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis. | J Neuroimmunol | 2025 | 40795619 | PubTator, text mining | PubMed |
| A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis. | Front Immunol | 2025 | 40787458 | PubTator, text mining | PubMed |
| Immune Modulatory Effects of PD-1/PD-L1 in Myasthenia Gravis: Insights From Peripheral Blood Mononuclear Cell Analysis. | FASEB J | 2025 | 40748491 | PubTator, text mining | PubMed |
| Unknown Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis: A New Mechanism of Action Beyond IgG Reduction. | Neurol Neuroimmunol Neuroinflamm | 2025 | 40743488 | PubTator, text mining | PubMed |
| Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis. | Eur J Neurol | 2025 | 40726281 | PubTator, text mining | PubMed |
Differential Scanning Calorimetry as a Monitoring Tool for the Effectiveness of Therapeutic Plasma Exchange in Anti-AChR Myasthenia Gravis, Anti-MuSK Myasthenia Gravis, and Myasthenic Syndrome: A Case Series. | J Clin Med | 2025 | 40725661 | PubTator, text mining | PubMed |
| Recent Advances in Antibody Discovery Using Ultrahigh-Throughput Droplet Microfluidics: Challenges and Future Perspectives. | Biosensors (Basel) | 2025 | 40710059 | PubTator, text mining | PubMed |
| Active Immunization for Inducing Autoimmune Muscle-Specific Kinase (MuSK) Myasthenia Gravis in Mice. | J Vis Exp | 2025 | 40690397 | PubTator, text mining | PubMed |
| Autoantibodies in myasthenia gravis. | Int Rev Neurobiol | 2025 | 40675742 | PubTator, text mining | PubMed |
| Blood and digital biomarkers in MG. | Int Rev Neurobiol | 2025 | 40675736 | PubTator, text mining | PubMed |
| Animal models of myasthenia gravis. | Int Rev Neurobiol | 2025 | 40675733 | PubTator, text mining | PubMed |
| Myasthenia Crisis as First Presentation of MuSk Positive Myasthenia Gravis: A Case Report. | JNMA J Nepal Med Assoc | 2025 | 40656929 | PubTator, text mining | PubMed |
| Magnesium Sulfate-Induced Ophthalmoplegia: A Rare Postnatal Complication. | Cureus | 2025 | 40656332 | PubTator, text mining | PubMed |
| COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey. | Muscle Nerve | 2025 | 40635622 | PubTator, text mining | PubMed |
| Subtype-specific atypical B cell profiles in myasthenia gravis reveal distinct immunopathological pathways. | Front Immunol | 2025 | 40607384 | PubTator, text mining | PubMed |
| Therapeutic strategies targeting complement in myasthenia gravis patients. | J Neurol | 2025 | 40601074 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4593/papers?page=8